Profile data is unavailable for this security.
About the company
JFL Life Sciences Limited is an India-based pharmaceutical company. The Company's business segment comprises manufacturing and selling of pharmaceutical products. It is engaged in domestic as well as international business. The Company's main product categories include Dry powder injections, Tablets & Capsules (B-Lactam) solid oral dosage form, Tablet, and capsules (General) and Oral Rehydration Solutions (ORS). Its beta-lactam dry powder injection products include Ampicillin Injection, Cefotaxime Sodium Injection, Cefazoline Sodium Injection, meropenem injection, amoxicillin injection, cefTAZidime injection, flucloxacillin injection, among others. Its beta-lactam tablets and capsule products include Cefadroxil Tablets, Cefadroxil Capsules, among others. Its general tablet and capsule products include Azithromycin Tablets, Iburofen Tablets, Ciprofloxacin Tablets, Ofloxacin Tablets, Paracetamol Tablets, among others. These products are offered in different milligrams (mg).
- Revenue in INR (TTM)800.66m
- Net income in INR47.93m
- Incorporated2010
- Employees39.00
- LocationJFL Life Sciences Ltd309, Satyam Mall, Satellite RoadAHMEDABAD 380015IndiaIND
- Phone+91 7 940036595
- Websitehttps://www.jfllifesciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicamen Organics Ltd | 394.30m | 45.74m | 305.37m | 114.00 | 6.80 | 0.9362 | 5.70 | 0.7745 | 3.84 | 3.84 | 33.10 | 27.88 | 0.716 | 3.30 | 1.63 | 3,458,737.00 | 8.31 | -- | 14.41 | -- | 38.03 | -- | 11.60 | -- | 1.46 | 10.71 | 0.3218 | -- | 51.11 | -- | 54.22 | -- | -- | -- |
| Medistep Healthcare Ltd | 634.72m | 54.27m | 336.77m | 9.00 | 5.46 | 0.9674 | 6.17 | 0.5306 | 4.34 | 4.34 | 49.60 | 24.50 | -- | -- | -- | 70,524,340.00 | -- | -- | -- | -- | 12.62 | -- | 8.55 | -- | 4.79 | 854.24 | 0.0167 | -- | 27.09 | -- | 24.54 | -- | -- | -- |
| JFL Life Sciences Ltd | 800.66m | 47.93m | 377.80m | 39.00 | 7.84 | -- | 6.32 | 0.4719 | 1.46 | 1.46 | 24.37 | -- | -- | -- | -- | -- | -- | 5.83 | -- | 10.64 | 22.23 | 18.28 | 6.02 | 5.73 | -- | 5.95 | -- | -- | 76.25 | 22.15 | 25.72 | 63.09 | -32.30 | -- |
| Jupiter Bioscience Ltd | -100.00bn | -100.00bn | 399.50m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.42 | -- | 5.61 | -- | 61.37 | -- | 17.32 | -- | -- | -- | 10.48 | 42.43 | 29.30 | 20.92 | 22.82 | 55.40 | -16.74 |
| Lasa Supergenerics Ltd | 952.91m | -361.68m | 431.37m | 66.00 | -- | 0.7656 | -- | 0.4527 | -7.57 | -7.57 | 19.58 | 11.25 | 0.8705 | 6.06 | 36.08 | 14,437,960.00 | -33.04 | -6.42 | -46.76 | -8.54 | 22.28 | 28.58 | -37.96 | -8.05 | 0.5203 | -14.70 | 0.1152 | -- | 36.53 | -3.16 | 32.09 | -- | -- | -- |
